What the research found

Researchers systematically reviewed eleven studies involving over 14,000 adults with diabetes who used health passports—either paper-based or digital tools that consolidate a patient's medical information—versus those receiving standard care. Seven of these were randomised controlled trials; the remainder were observational or qualitative studies.

Meta-analysis of five studies found small, statistically significant reductions in HbA1c and total cholesterol among passport users. However, when researchers looked across all studies, most reported little meaningful change in body mass index, blood pressure, fasting glucose, or cholesterol. Patients did report subjective improvements: they found the passports easier to use, felt they had better ownership of their health, and experienced improved communication with their care team.

The overall quality of evidence was rated as low to very low, largely because the included studies had methodological limitations and unclear or high risk of bias across several domains.

Why it matters for you

If you're using MyKine to track blood work, medications, or supplements, you're already doing what a health passport aims to do—consolidating your health data in one place. This review suggests that having consolidated information probably matters less than how you use it and what you do with it. The modest HbA1c improvements hint that the tool alone doesn't drive better outcomes; engagement and follow-through do.

For MyKine users managing glucose or metabolic health, the takeaway is pragmatic: a passport or app is infrastructure. The real work happens when you act on the data—adjusting training timing around glucose readings, modifying supplement stacks based on lipid panels, or using your records to spot trends that inform conversations with your doctor. The patient-reported benefits (better usability, stronger collaboration) align with what tracking tools actually do well.

If you're considering adopting formal health passports alongside apps like MyKine, or sharing your consolidated data with clinicians, this suggests it can support better care—but the effect size in hard biomarkers remains unclear.

Caveats

  • Low certainty of evidence: The included studies were heterogeneous in design and quality; results should be treated as preliminary rather than definitive
  • Mixed methodological quality: Multiple studies carried high or unclear bias; only seven of eleven were randomised controlled trials
  • Gap between statistics and reality: Meta-analysis showed HbA1c reduction, but narrative review across all studies found little improvement in most metabolic outcomes, suggesting publication or reporting bias
  • Subjective vs. objective outcomes: Patient satisfaction improved; objective health markers largely did not—these may be separate effects
  • No data on which passport features drive benefit: The review doesn't identify whether specific design elements, integration with clinicians, or reminder functionality are the active ingredients